Mustang Bio Inc (MBIO) Actualités

Form 8-K - Current report

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Form DEF 14C - Other definitive information statements

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Form PRE 14C - Other preliminary information statements

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 8-K - Current report

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Announces Closing of $8 Million Public Offering

WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Mustang Bio Announces Pricing of $8 Million Public Offering

WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...